Central Nervous System (CNS) Stimulant Drugs Market to grow at a CAGR of 5.74 by 2026 | Rise in CNS Disorders to Boost Growth | 17000+ Technavio Reports – PR Newswire

Searching for your content…
In-Language News
Contact Us
888-776-0942
from 8 AM – 10 PM ET
News provided by
Mar 14, 2022, 11:30 ET
Share this article
NEW YORK, March 14, 2022 /PRNewswire/ — The central nervous system (CNS) stimulant drugs market is fragmented and the vendors are deploying growth strategies such as investment in R and D to compete in the market. Astellas Pharma Inc., Biogen Inc., Endo International Plc, GlaxoSmithKline Plc, Highland Therapeutics Inc., Jazz Pharmaceuticals Plc, Johnson and Johnson Inc., KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, Sanofi SA, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Tris Pharma Inc., UCB SA, and Viatris Inc. are some of the major market participants. The central nervous system (CNS) stimulant drugs market is set to grow by USD 5.95 billion from 2021 to 2026, progressing at a CAGR of 5.74% according to the latest market forecast report by Technavio.
To know the exact growth variance and the Y-O-Y growth rate – Request a free sample report.
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Scope
 Our central nervous system (CNS) stimulant drugs market report covers the following areas:
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Drivers & Challenges
The key factor driving the central nervous system (CNS) stimulant drugs market growth is the rise in CNS disorders such as sleep apnea, narcolepsy, and attention-deficit hyperactivity disorder worldwide. As per Le et al. 2013, the global prevalence of attention-deficit hyperactivity disorder in children and adolescents was estimated to be 5.3%-5.9%, while in Europe, 4.6% of children and adolescents were estimated to have attention-deficit hyperactivity disorder. According to the CDC, in the US, 5% of children have attention-deficit hyperactivity disorder. In 2016, an estimated 6.1 million children were diagnosed with attention-deficit hyperactivity disorder in the US.
However,  the key challenges to the global central nervous system (CNS) stimulant drugs market growth are the numerous side effects of drugs. For instance, the medication for attention-deficit hyperactivity disorder is effective in reducing the symptoms of the disease. However, the medication is also associated with side effects. Medications such as methylphenidates, including RITALIN, Focalin, Metadate, and CONCERTA, whereas amphetamines such as DEXEDRINE, Adderall, and VYVANSE have some potential side effects such as sleep problems, reduced appetite, increased blood pressure, headaches, stomach ache, nervousness, and moodiness, and irritability. Furthermore, amphetamines have been used to improve alertness in narcolepsy. These medications are the most effective in reducing sleepiness.
To know about more drivers & challenges – Download a free sample now!
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Segmentation
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Revenue Generating Segment & Regional Analysis
For more insights on the market share of various segments – Download a free sample now!
Central Nervous System (CNS) Stimulant Drugs Market 2022-2026: Key Highlights
Subscribe to our "Lite Plan" billed annually at USD 3000 that enables you to download 3 reports/year and view 3 reports/month.
Related Reports:
Central Nervous System (CNS) Stimulant Drugs Market Scope
Report Coverage
Details
Page number
120
Base year
2021
Forecast period
2022-2026
Growth momentum & CAGR
Accelerate at a CAGR of 5.74%
Market growth 2022-2026
USD 5.95 billion
Market structure
Fragmented
YoY growth (%)
5.52
Performing market contribution
North America at 46%
Competitive landscape
Leading companies, competitive strategies, consumer engagement scope
Companies profiled
Astellas Pharma Inc., Biogen Inc., Endo International Plc, GlaxoSmithKline Plc, Highland Therapeutics Inc., Jazz Pharmaceuticals Plc, Johnson and Johnson Inc., KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, Sanofi SA, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Tris Pharma Inc., UCB SA, and Viatris Inc.
Market Dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period,
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table Of Contents :
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Application
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET

source

Add a Comment

Your email address will not be published.